| 1 | technical storage or access | | | | | | | 5 | 0.57% |
| 2 | storage or access is | | | | | | | 3 | 0.34% |
| 3 | july 3 2024 200pm | | | | | | | 2 | 0.23% |
| 4 | storage or access that | | | | | | | 2 | 0.23% |
| 5 | july 1 2024 640pm | | | | | | | 2 | 0.23% |
| 6 | july 1 2024 800pm | | | | | | | 2 | 0.23% |
| 7 | july 1 2024 535pm | | | | | | | 2 | 0.23% |
| 8 | imaging computational methods for | | | | | | | 2 | 0.23% |
| 9 | necessary for the legitimate | | | | | | | 2 | 0.23% |
| 10 | june 30 2024 630pm | | | | | | | 2 | 0.23% |
| 11 | from research to practice | | | | | | | 2 | 0.23% |
| 12 | by the subscriber or | | | | | | | 2 | 0.23% |
| 13 | july 2 2024 945am | | | | | | | 2 | 0.23% |
| 14 | or access that is | | | | | | | 2 | 0.23% |
| 15 | access that is used | | | | | | | 2 | 0.23% |
| 16 | july 2 2024 800pm | | | | | | | 2 | 0.23% |
| 17 | is used exclusively for | | | | | | | 2 | 0.23% |
| 18 | that is used exclusively | | | | | | | 2 | 0.23% |
| 19 | the subscriber or user | | | | | | | 2 | 0.23% |
| 20 | the technical storage or | | | | | | | 2 | 0.23% |
| 21 | validation and uncertainties quantification | | | | | | | 1 | 0.11% |
| 22 | or user or for | | | | | | | 1 | 0.11% |
| 23 | for biomedical applications humanoid | | | | | | | 1 | 0.11% |
| 24 | manufacturing for biomedical applications | | | | | | | 1 | 0.11% |
| 25 | additive manufacturing for biomedical | | | | | | | 1 | 0.11% |
| 26 | biology additive manufacturing for | | | | | | | 1 | 0.11% |
| 27 | the use of a | | | | | | | 1 | 0.11% |
| 28 | subscriber or user or | | | | | | | 1 | 0.11% |
| 29 | use of a specific | | | | | | | 1 | 0.11% |
| 30 | biomechanics rehabilitation impactinjury biomechanics | | | | | | | 1 | 0.11% |
| 31 | of a specific service | | | | | | | 1 | 0.11% |
| 32 | and uncertainties quantification computational | | | | | | | 1 | 0.11% |
| 33 | verification validation and uncertainties | | | | | | | 1 | 0.11% |
| 34 | emerging topics in biomechanics | | | | | | | 1 | 0.11% |
| 35 | a specific service explicitly | | | | | | | 1 | 0.11% |
| 36 | occupational biomechanics rehabilitation impactinjury | | | | | | | 1 | 0.11% |
| 37 | specific service explicitly requested | | | | | | | 1 | 0.11% |
| 38 | in vivo clinical trials | | | | | | | 1 | 0.11% |
| 39 | requested by the subscriber | | | | | | | 1 | 0.11% |
| 40 | and in vivo clinical | | | | | | | 1 | 0.11% |